Alaproclate

DB13233ExperimentalSmall molecule

Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. Development was discontinued due to concerns over hepatotoxicity... Alaproclate has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine.

Chemical structure of Alaproclate
Mechanism
Curator reviewed
Formula / weight
C13H18ClNO2 · 255.74 g/mol (avg)
Code names
GEA-654

Resolves to

Compound
UNIIC4R42570ZOCAS60719-82-6ChEMBLCHEMBL36591ChEBI91544PubChem2081KEGGD02787
Clinical / RWD
ATCN06AB07
Structure
InChIKeyFZSPJBYOKQPKCD-UHFFFAOYSA-NSMILESCC(N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1
Targets
P31645SLC6A4P16389KCNA2Q5BJF2TMEM97

What you can answer from here — as of August 30, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,473Drug interactionsStructured to mechanism, not free text
Sign in
1ATC codeIncluding every combination product, plus 18 drug categories
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Alaproclate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In